Hemogenyx Pharmaceuticals Plc (LON: HEMO)

London flag London · Delayed Price · Currency is GBP · Price in GBX
370.00
+7.55 (2.08%)
Jan 23, 2025, 8:21 AM BST
13,553%
Market Cap 12.70M
Revenue (ttm) n/a
Net Income (ttm) -5.18M
Shares Out 3.50M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,472
Average Volume 8,273
Open 355.00
Previous Close 362.45
Day's Range 355.00 - 370.00
52-Week Range 270.00 - 2,853.60
Beta 3.35
RSI 46.26
Earnings Date Dec 27, 2024

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company’s lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hema... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 17
Stock Exchange London Stock Exchange
Ticker Symbol HEMO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.